Halozyme Therapeutics (HALO) vs Twist Bioscience (TWST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Twist Bioscience (TWST) has outperformed Halozyme Therapeutics (HALO) over the past year, gaining 363.7% versus a gain of 68.5%. Over five years, HALO leads with a +190.9% price change compared with +34.8% for TWST. Halozyme Therapeutics is the larger company by market cap ($12.47 billion vs $10.08 billion), about 1.2 times the size.
Halozyme Therapeutics converts more of its revenue into profit, with a net margin of 22.7% versus -20.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HALO | TWST |
|---|---|---|
| Share price | $109.84 | $152.05 |
| Market cap | $12.47B | $10.08B |
| 1-day change | -0.86% | -2.31% |
| YTD return | +63.21% | +379.35% |
| 1-year return | +68.47% | +363.71% |
| 5-year return | +190.89% | +34.80% |
| P/E ratio (TTM) | 32.12 | — |
| Forward P/E | 10.33 | — |
| EPS (TTM) | $3.42 | $-2.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.40B | $376.57M |
| Revenue growth (YoY) | +37.55% | +20.32% |
| Net income (latest FY) | $316.89M | $-77.67M |
| Gross margin | 83.62% | 50.72% |
| Operating margin | 33.58% | -36.18% |
| Net margin | 22.69% | -20.63% |
| 52-week high | $116.85 | $219.71 |
| 52-week low | $61.23 | $23.30 |
| Distance from 52-week high | -6.00% | -30.80% |
| Analyst consensus | buy | buy |
| Avg. price target upside | -9.36% | -1.13% |
| Average volume | 2.18M | 2.04M |
| Shares outstanding | 113.50M | 66.30M |
| Employees | 423 | 979 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TWST has outperformed HALO by 295.2 percentage points over the past year.
- Halozyme Therapeutics is more profitable, keeping 22.7 cents of every revenue dollar as net income versus -20.6 cents for Twist Bioscience.
- Halozyme Therapeutics grew revenue faster in its latest fiscal year (+37.55% vs +20.32%).
About Halozyme Therapeutics
HALO stock →Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 423 employees
About Twist Bioscience
TWST stock →Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 979 employees
HALO vs TWST FAQ
Which is bigger, Halozyme Therapeutics or Twist Bioscience?
Halozyme Therapeutics (HALO) is larger, with a market capitalization of $12.47B compared with $10.08B for Twist Bioscience (TWST).
Which stock has performed better over the past year, HALO or TWST?
TWST returned +363.71% over the past 12 months, compared with +68.47% for HALO (price return, excluding dividends). Past performance does not predict future results.
Are Halozyme Therapeutics and Twist Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.